Whole brain irradiation and temozolomide based chemotherapy in melanoma brain metastases
- 55 Downloads
Whole brain irradiation (WBRT) remains a recommended treatment for patients with brain metastases from malignant melanoma in terms of symptom palliation, especially when extracranial systemic disease is present. Temozolomide (TMZ) has shown efficacy in the treatment of metastatic melanoma. The objective was to evaluate the potential benefit in survival of two different schedules of total dose and fractionation (20 Gy/5 fractions vs 30 Gy/10 fractions) and further TMZ based chemotherapy.
Materials and method
We have conducted a retrospective study in a group of twenty-one patients (RTOG Recursive Partitioning Analysis class II) of the use of WBRT with 20 Gy/5 fractions (n=11) and 30 Gy/10 fractions (n=10). All patients received further TMZ based chemotherapy administered as a single chemotherapeutic agent or in combination with chemo-immunotherapy.
Prognostic variables such as: age, Karnofsky performance status, extracranial metastases and number of brain metastases, were analyzed in both groups of treatment without statistically significant differences. The median survival time (MST) for WBRT 20 Gy group was 4 months (CI 95%: range 2–6 months) and for WBRT 30 Gy group was 4 months (CI 95%: range 0–7 months) without statistically significant differences (Log rank p=0.74). There was one complete response and two partial responses.
The results suggest that MST was not significantly affected by the total dose/fractionation schedule.
Key wordsmalignant melanoma brain metastases radiotherapy chemotherapy temozolomide
Unable to display preview. Download preview PDF.
- 4.Buchsbaum JC, Suh JH, Lee S-Y, Chidel MA, Greskovich JF, Barnett GH. Survival by Radiation Therapy Oncology Group Recursive Partitioning Analysis Class and treatment modality in patients with brain metastases from malignant melanoma. A retrospective study, Cancer. 2002;94:2265–72.PubMedCrossRefGoogle Scholar
- 6.Bleehen NM, Newlands ES, Lee SM, et al. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol. 1995;15:910–3.Google Scholar
- 7.Franke W, Neumann N, Richter-Hintz D, Ruzicka T, Klaus W. Temozolomide-A promising agent in the therapy of brain metastases in malignant melanoma. In: American Society of Clinical Oncology 36th Annual Meeting, New Orleans, May 20–23, 2000, Prog Proc Am Soc Clin Oncol. 2000;19:575.Google Scholar
- 9.Conill C, Puig S, Toscas I, Castel T. Complete response of cerebral metastasic melanoma after a combined treatment of radiotherapy and temozolomide. Med Clin (Barc). 2002;119(19):758–9.Google Scholar